Short answer
Organon & Co (OGN) filed an 8-K current report with the SEC on July 17, 2026 reporting Item 8.01 (Other Events). Merger litigation seeks to delay July 23 stockholder vote and compel further proxy disclosures.
Organon & Co 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Merger litigation seeks to delay July 23 stockholder vote and compel further proxy disclosures
- Organon voluntarily supplemented its proxy to reduce litigation and transaction-delay risk, while denying wrongdoing
- Preliminary Sun Pharma synergy estimate: approximately $700 million across commercial, procurement, R&D and corporate functions
- Updated projections show 2026 revenue $6,252 million, Adjusted EBITDA $1,894 million and unlevered free cash flow $1,010 million
- March 31 net debt $7,530 million and estimated adjusted LTM EBITDA $1,832 million, highlighting meaningful transaction leverage
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Organon & Co 8-K filings
Get the next OGN 8-K as it lands
Follow OGN for push alerts, or ask the research agent what this filing means.